Anti-Mullerian hormone levels in female cancer patients of reproductive age in Indonesia: A cross-sectional study

• DOI: 10.12688/f1000research.15728.1
• Publication Date: 2019-02-06T09:20:06Z
• Authors: Achmad Kemal Harzif; Budi Wiweko; Putri Addina; Kartika Iswaranti; Melisa Silvia; Ana Mariana; Kresna Mutia; Kanadi Sumapraja; R Muharam; Gita Pratama
• Keywords: Ovarian Reserve; Anti-Müllerian hormone

<ns3:p><ns3:bold>Background:</ns3:bold> Efforts in reproductive preservation for cancer patients have become one of the important aspects management. In fact, decline function is known to occur after exposure anti-cancer treatments. Measuring anti-Müllerian hormone (AMH) levels be best parameter predicting ovarian reserves, which indicates function. total, 68% survivors age who underwent treatments suffer from infertility. Meanwhile, reserves also decrease with increasing age. There ongoing debate on whether could reduced long before therapy. Therefore, it know or This can help predict such cases and effectiveness efforts.</ns3:p><ns3:p> <ns3:bold>Methods:</ns3:bold> A cross-sectional study was conducted, comparing AMH 44 female therapy, non-cancer (age matched)<ns3:italic>.</ns3:italic> The biological ages both groups were adjusted using Indonesian Kalkulator Oocytes.</ns3:p><ns3:p> <ns3:bold>Results: </ns3:bold>The median 28 years old. group found significantly lower contrast those (1.11 [0.08-4.65] ng/ml vs. 3.99 [1.19- 8.7]; p- value &lt;0.001). 10 older than that group, indicating aging occurs earlier patients.</ns3:p><ns3:p> <ns3:bold>Conclusions:</ns3:bold> already given an age, patients. Proper counseling implementation fertility-preserving methods highly recommended this patients.</ns3:p>